Keywords: oncology; cancer; oncologic emergencies; checkpoint inhibitor; toxicity; toxicities; chemotherapy; immunotherapy; pneumonitis; colitis; thyroiditis; hypophysitis; dermatitis; immune checkpoint inhibitor; immunotherapy-related adverse events; irAEs; ICPI;